autologIX for Sexual Wellness
“First placebo-controlled RCT: 69% of PRP patients achieved clinically meaningful improvement in erectile function versus 27% placebo.”
The scientific rationale
Sexual wellness represents an emerging but clinically validated PRP application, anchored by the first double-blind, placebo-controlled RCT in the field. Poulios et al. (2021) demonstrated that at 6 months, 69% of PRP-treated patients versus 27% of placebo achieved the minimal clinically important difference (MCID) in erectile function scores (P < 0.001). A subsequent meta-analysis of 3 RCTs confirmed significant improvement (MD 3.28, P < 0.001).
The biological rationale centers on the penile microvasculature. Erectile dysfunction involves endothelial dysfunction, smooth muscle atrophy, and fibrosis of the corpora cavernosa — processes driven by reduced angiogenesis, chronic inflammation, and progressive tissue remodeling. PRP delivers the angiogenic (VEGF, PDGF), anti-fibrotic (HGF), and tissue-remodeling (TGF-beta, fibronectin) signals needed to address these mechanisms simultaneously.
autologIX adds the protein enrichment dimension: concentrated HGF provides anti-fibrotic activity relevant to corporal tissue remodeling. Concentrated A2M inhibits the MMP-driven extracellular matrix degradation that contributes to cavernosal fibrosis. Characterized exosomes carry miRNAs involved in angiogenic and anti-inflammatory signaling. The higher output volume (6–7 mL) accommodates the bilateral intracavernosal injection protocol (divided between two corpora).
For female sexual wellness, evidence is earlier but favorable. Prospective studies show improvements in arousal, lubrication, and orgasm scores following PRP injection. A 2025 scoping review of 43 studies found PRP improved symptoms for vulvar lichen sclerosus and vulvovaginal atrophy.
Clinical studies investigating autologIX outcomes for sexual wellness are in development.
Key published evidence
Poulios et al. 2021 — First double-blind placebo-controlled RCT for PRP in erectile dysfunction. 69% versus 27% achieved MCID at 6 months (P < 0.001). Journal of Sexual Medicine.
Falcone et al. 2025 — First comprehensive meta-analysis for PRP in ED. Significant IIEF improvement (MD 3.28, P < 0.001). World Journal of Men’s Health.
Zhou et al. 2025 — Confirmed PRP improvements at 12 and 24 weeks but not at 4 weeks, supporting multi-session protocols. The Aging Male.
Limitations
The evidence base for PRP in sexual wellness is early — one pivotal RCT for ED and no large RCTs for female applications. No autologIX-specific data exist.
References
- Poulios E et al. J Sex Med. 2021;18(5):926-935. https://pubmed.ncbi.nlm.nih.gov/33814366/
- Falcone M et al. World J Mens Health. 2025;43(1):1-10. https://pubmed.ncbi.nlm.nih.gov/39360626/
- Zhou Y et al. Aging Male. 2025;28(1):2467220. https://pubmed.ncbi.nlm.nih.gov/39998904/
